018IC - How to Use Prostate-Specific Membrane Antigen-Positron Emission Tomography/CT in the Management of Relapsing Prostate Cancer Patients following Local Therapy with Curative Intent

Friday, April 28, 2023

4:00 PM – 6:00 PM CST

Location: S102B

Instructional Course Director(s)

Axel Heidenreich, MD

Director and Chairman
University of Cologne

Instructional Course Faculty(s)

RK

Robert Karnes, MD
JM

Judd Moul, MD, FACS (he/him/his)

James H Semans MD Professor of Surgery
Duke University

Course Description: The learners will understand the following critical clinical aspects with regard to the clinical application of prostate-specific membrane antigen (PSMA)-positron emission tomography (PET)/CT scanning mode of action of PSMA-PET/CT
- pitfalls of PSMA-PET/CT
- diagnostic accuracy depending on PSA, PSA double time, prostate cancer histology
- application of PSMA-PET/CT to identify patients with intrapelvic nodal relapse who will benefit from local therapy such as salvage lymphadenectomy or stereotactic radiation therapy
- application of PSMA-PET/CT to identify patients with organ-confined radiorecurrent local relapse of prostate cancer who might be candidates for radical salvage prostatectomy
- application of new PSMA-PET/CT-based clinical staging system as a standardized reporting framework

Learning Objectives:

Identify the clinical scenario in which PSMA-PET/CT is most helpful to identify the localization and extent of locoregional or systemic metastatic disease.
Identify the pitfalls of false-positive and false-negative PSMA-PET/CT findings.
Apply the findings of PSMA-PET/CT for the best individual therapeutic approach.
Identify patients with radiorecurrent organ-confined prostate cancer.
Identify those patients who are candidates for local therapy of oligometastatic disease in relapsing prostate cancer.
Identify patients who might benefit most from secondary local therapy such as radical salvage prostatectomy or salvage radiation therapy.